XML 43 R10.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Consolidated Statements of Cash Flows (USD $)
In Millions
6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 416.8 $ 326.2
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 132.3 129.1
Share based compensation 34.9 26.7
Gain on sale of non-current investments 0 (11.1)
Other (5.7) 11.0
Movement in deferred taxes 17.7 58.8
Equity in earnings of equity method investees (2.4) (0.5)
Loss/(gain) on sale of product rights 3.5 (4.1)
Changes in operating assets and liabilities:    
Increase in accounts receivable (56.2) (43.9)
Increase in sales deduction accrual 66.1 154.3
Increase in inventory (30.6) (50.1)
Increase in prepayments and other assets (13.8) (83.3)
Decrease in accounts payable and other liabilities (77.1) (43.2)
Net cash provided by operating activities 485.5 469.9
CASH FLOWS FROM INVESTING ACTIVITIES:    
Movements in restricted cash 4.8 6.0
Purchases of subsidiary undertakings, net of cash acquired (719.7) 0
Purchases of non-current investments (4.5) 0
Purchases of property, plant and equipment ("PP&E") (95.0) (208.1)
Purchases of intangible assets 0 (2.7)
Proceeds from disposal of non-current investments, PP&E and product rights 6.9 2.1
Returns of equity investments and proceeds from short term investments 1.6 0
Net cash used in investing activities (805.9) (202.7)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from drawings of revolving credit facility 30.0 0
Repayment of debt acquired with ABH (13.1) 0
Payment under building finance obligation (0.4) (1.3)
Extinguishment of building finance obligation 0 (43.1)
Tax benefit of stock based compensation 18.8 4.4
Proceeds from exercise of options 0.8 1.8
Payment of dividend (60.5) (49.8)
Payments to acquire shares by ESOT (63.9) (1.7)
Net cash used in financing activities (88.3) (89.7)
Net (decrease)/increase in cash and cash equivalents (406.0) 183.6
Effect of foreign exchange rate changes on cash and cash equivalents 2.7 6.1
Cash and cash equivalents at beginning of period 550.6 498.9
Cash and cash equivalents at end of period 144.6 682.5
Supplemental information associated with continuing operations:    
Interest paid (16.2) (13.0)
Income taxes paid (147.7) (205.0)
Non cash investing and financing activities:    
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment $ 0 $ 9.1